GSK (NYSE:GSK) Reaches New 52-Week Low – Here’s Why

Shares of GSK plc (NYSE:GSK) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $32.66 and last traded at $32.66, with a volume of 27544 shares trading hands. The stock had previously closed at $33.09.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Down 1.5 %

The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $67.54 billion, a price-to-earnings ratio of 21.16, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The business has a fifty day moving average of $34.38 and a 200-day moving average of $38.17.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.82%. GSK’s dividend payout ratio (DPR) is 95.45%.

Hedge Funds Weigh In On GSK

Large investors have recently made changes to their positions in the business. Eastern Bank purchased a new stake in GSK during the third quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners lifted its stake in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in GSK during the second quarter valued at about $37,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.